CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. Benzoyl peroxide is an oxidizing agent with bactericidal activity against Propionibacterium acnes, and also has keratolytic and comedolytic effects.
| Metabolism | Clindamycin phosphate is hydrolyzed to clindamycin; clindamycin is primarily metabolized by CYP3A4 and to a lesser extent by CYP3A5. Benzoyl peroxide is metabolized to benzoic acid and then excreted in urine. |
| Excretion | Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. After topical application, systemic absorption is minimal (approximately 10% of applied dose). The absorbed clindamycin is primarily excreted via the kidneys (10% unchanged, 3% as metabolites) and biliary/fecal routes (approximately 4%). Benzoyl peroxide is converted to benzoic acid, which is up to 87% excreted in urine as hippuric acid after conjugation with glycine. Overall, for the combination, renal excretion accounts for ~10%, biliary/fecal ~4%, remainder remains unabsorbed or metabolized locally. |
| Half-life | Terminal elimination half-life of clindamycin after topical application is approximately 2.4 hours. However, due to slow release from skin depot, effective half-life extends to 6–12 hours, supporting twice-daily dosing. Benzoyl peroxide has a very short half-life (<1 minute) on skin due to rapid decomposition; systemic half-life of benzoic acid is ~0.9 hours. |
| Protein binding | Clindamycin is 60–94% bound to serum proteins (mainly albumin). Benzoyl peroxide is not systemically absorbed in significant amounts; its metabolite benzoic acid is 20–40% bound to albumin. |
| Volume of Distribution | For clindamycin, apparent volume of distribution is approximately 0.6–1.2 L/kg. With topical application, the systemic Vd is low due to limited absorption. Benzoyl peroxide is not systemically distributed. |
| Bioavailability | Topical: Clindamycin phosphate systemic bioavailability is about <5% (range 1–10%) after application to intact skin. Benzoyl peroxide bioavailability is negligible (<1%) as it is converted to benzoic acid on the skin; benzoic acid may be absorbed with bioavailability of ~5% but rapidly metabolized. |
| Onset of Action | Clinical effect (reduction of inflammatory lesions) is typically observed within 2–4 weeks of twice-daily topical application. Initial improvement may be seen as early as 2 weeks, with maximal effect at 10–12 weeks. |
| Duration of Action | After cessation of application, clindamycin's antibacterial effect persists for approximately 24–48 hours due to tissue binding and slow release. Benzoyl peroxide has no residual antimicrobial effect beyond the application period. The clinical duration of effect (lesion reduction) lasts for several weeks, but sustained use is required to maintain control. |
| Molecular Weight | Clindamycin phosphate: 504.96 Da (clindamycin base: 424.98 Da); benzoyl peroxide: 242.23 Da |
Apply a thin film to affected areas twice daily (morning and evening).
| Dosage form | GEL |
| Renal impairment | No adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution due to limited data. |
| Liver impairment | No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A and B). Safety and efficacy not established in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Approved for children ≥12 years: apply thin film to affected areas twice daily. For children <12 years: safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required; however, elderly patients may have increased sensitivity to local adverse effects. Use with caution. |
| 1st trimester | Generally considered safe topically, but avoid systemic use due to risk of pseudomembranous colitis. |
| 2nd trimester | Topical use considered safe; systemic absorption minimal. |
| 3rd trimester | Topical use considered safe; avoid systemic use near term due to potential neonatal effects. |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Placental transfer | Clindamycin crosses the placenta; benzoyl peroxide is degraded to benzoic acid, which crosses placenta. Systemic absorption from topical use is minimal (<10%). |
| Breastfeeding |
■ FDA Black Box Warning
None
| Common Effects | Diarrhea (including C. difficile) |
| Serious Effects |
Hypersensitivity to clindamycin, benzoyl peroxide, or any componentHistory of regional enteritis, ulcerative colitis, or antibiotic-associated colitis
| Precautions | Clostridium difficile associated diarrhea (CDAD) may occur with topical clindamycin; if diarrhea occurs, discontinue use., Avoid contact with eyes, mouth, lips, and mucous membranes., May cause skin irritation, erythema, peeling, and dryness; reduce frequency or discontinue if severe., Concomitant use with other topical acne products may increase irritation., Use caution in patients with history of colitis or inflammatory bowel disease. |
| Food/Dietary | No specific food interactions. Avoid excessive sun exposure and tanning beds as product may increase photosensitivity. |
Loading safety data…
| Topical application of clindamycin/benzoyl peroxide results in minimal systemic absorption; it is considered compatible with breastfeeding. However, avoid application to the breast area to prevent infant ingestion. |
| Lactation Rating | L2 (Safe - Limited Data) or 'Safe' |
| Teratogenic Risk | Clindamycin phosphate: No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. Benzoyl peroxide: Not absorbed systemically; no fetal risk expected. Overall: Low risk; use only if clearly needed. First trimester: No specific risks. Second/Third trimester: No evidence of fetal harm. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Monitor for maternal allergic reactions or local skin irritation. |
| Fertility Effects | Clindamycin: No evidence of impaired fertility in animal studies. Benzoyl peroxide: No systemic exposure; no effect on fertility expected. |
| Clinical Pearls | Avoid use in patients with history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Do not apply to large areas of broken skin. Use with caution in atopic individuals due to increased risk of skin irritation. Combination therapy is effective for inflammatory and non-inflammatory acne lesions. May cause temporary yellowing of skin or fabrics; avoid contact with hair and clothing. |
| Patient Advice | Apply a thin layer to affected areas once daily in the evening. · Wash face with mild cleanser and pat dry before application. · Avoid contact with eyes, lips, mouth, and mucous membranes. · May cause skin dryness, peeling, or redness; use moisturizer if needed. · Do not use other topical acne products without consulting your doctor. · Notify your doctor if you develop diarrhea, abdominal cramps, or bloody stools. · Stop use and seek medical attention if severe allergic reaction occurs. · Keep away from heat, open flames, and smoking while applying and until dry. |